*
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Kura Oncology’s 8K filing here.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Read More
- Five stocks we like better than Kura Oncology
- Election Stocks: How Elections Affect the Stock Market
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- Most active stocks: Dollar volume vs share volume
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- How to Invest in Blue Chip Stocks
- How Cigna Remains at the Top of the Health Insurance Food Chain
